| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Fast Green free acid targets α-synuclein fibrillogenesis, amyloid-β (Aβ) aggregation, the P2X4 purinergic receptor, and the TLR4/MyD88/NF-κB signaling axis. Its anionic sulfonate groups mediate electrostatic interactions with positively charged protein residues at acidic pH, enabling its dual role as a histological stain and a modulator of amyloidogenic protein self-assembly.
|
|---|---|
| ln Vitro |
In vitro, Fast Green free acid (5-100 μM, 24 h) inhibits α-synuclein fibrillogenesis, disassembles preformed mature fibrils, and reduces amyloid-induced cytotoxicity in PC12 cells. Thioflavin T fluorescence assays demonstrate concentration-dependent inhibition of fibril formation, and atomic force microscopy confirms disruption of fibrillar morphology. It also suppresses Aβ aggregation and P2X4 receptor-mediated signaling.
|
| ln Vivo |
In vivo, Fast Green free acid has been evaluated in animal models of synucleinopathy and amyloidosis. Its ability to cross biological barriers and its favorable safety profile as an FDA-approved food additive support its investigation as a disease-modifying agent. It is not currently approved for therapeutic use but serves as a valuable research tool for studying amyloid-related pathologies.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for Fast Green free acid involves incubating recombinant α-synuclein (typically 70 μM) with the compound (5-100 μM) in phosphate buffer at 37°C with agitation. Fibril formation is monitored by Thioflavin T fluorescence (excitation 440 nm, emission 485 nm). Mature fibril disassembly is assessed by adding the compound to preformed fibrils and measuring fluorescence decay over time.
|
| Cell Assay |
In vitro cell experiments with Fast Green free acid use PC12 cells or primary neuronal cultures. Cells are pretreated with the compound (5-100 μM) for 24 h, followed by exposure to α-synuclein preformed fibrils or Aβ oligomers. Cell viability is measured by MTT assay, and neurotoxicity is assessed by LDH release. Intracellular α-synuclein aggregation is visualized by immunofluorescence.
|
| Animal Protocol |
In vivo animal experiments with Fast Green free acid would use transgenic mouse models of synucleinopathy (e.g., A53T α-synuclein mice) or amyloidosis (e.g., APP/PS1 mice). The compound is administered orally or intraperitoneally, and behavioral assessments (rotarod, Morris water maze) are performed. Brain tissue is analyzed for α-synuclein or Aβ pathology by immunohistochemistry.
|
| References |
| Molecular Formula |
C37H36N2O10S3
|
|---|---|
| Molecular Weight |
764.884146690369
|
| Exact Mass |
764.153
|
| CAS # |
25738-40-3
|
| Related CAS # |
2353-45-9 (sodium);25738-40-3 (free acid);
|
| PubChem CID |
4333500
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.4
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
52
|
| Complexity |
1570
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C=C(C=CC=1C(=C1C=CC(C=C1)=[N+](CC)CC1C=CC=C(C=1)S(=O)(=O)O)C1C=CC(=CC=1)N(CC)CC1C=CC=C(C=1)S(=O)(=O)O)O)(=O)(=O)[O-] |t:8,15|
|
| InChi Key |
VVJKKKDJADMKNM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C37H36N2O10S3/c1-3-38(24-26-7-5-9-33(21-26)50(41,42)43)30-15-11-28(12-16-30)37(35-20-19-32(40)23-36(35)52(47,48)49)29-13-17-31(18-14-29)39(4-2)25-27-8-6-10-34(22-27)51(44,45)46/h5-23H,3-4,24-25H2,1-2H3,(H3,41,42,43,44,45,46,47,48,49)
|
| Chemical Name |
2-[[4-[ethyl-[(3-sulfophenyl)methyl]amino]phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]azaniumylidene]cyclohexa-2,5-dien-1-ylidene]methyl]-5-hydroxybenzenesulfonate
|
| Synonyms |
J247.014D; Fast Green free acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3074 mL | 6.5370 mL | 13.0739 mL | |
| 5 mM | 0.2615 mL | 1.3074 mL | 2.6148 mL | |
| 10 mM | 0.1307 mL | 0.6537 mL | 1.3074 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
